Načítá se...
New Antihyperglycemic Drugs and Heart Failure: Synopsis of Basic and Clinical Data
The assessment of the cardiovascular safety profile of any newly developed antihyperglycemic drug is mandatory before registration, as a meta-analysis raised alarm describing a significant increase in myocardial infarction with the thiazolidinedione rosiglitazone. The first results from completed ca...
Uloženo v:
| Vydáno v: | Biomed Res Int |
|---|---|
| Hlavní autoři: | , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Hindawi
2017
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5574229/ https://ncbi.nlm.nih.gov/pubmed/28894748 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2017/1253425 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|